The purpose of this study is to see if the study drug called spironolactone reduces fibrous
(stiffening) in heart muscle tissue and improves heart function. Subjects from the study
titled "Heart Failure in Congenital Heart Disease: the role of myocardial fibrosis" who have
evidence of heart dysfunction and/or evidence of fibrosis (stiffening) in the heart muscle
will be asked to take part in this study.
Phase:
Phase 2
Details
Lead Sponsor:
Oregon Health and Science University
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI) Oregon Clinical and Translational Research Institute